65,437 trials
Liver Transplantation
Primary: Renal Function Assessed by Estimated Glomerular Filtartion Rate (eGFR) — 85.50; 80.26 mL/min/1.73m^2 — p=0.3013
Dental Caries
Primary: Presence or Absence of Elevated Luminescence — 61.7; 17.3; 6.0; 10.2 % active teeth with luminescence
Alzheimer's Disease
Primary: Number of Participants Experiencing an Adverse Event (AE) — 1; 5; 1 Participants
Teen Drivers · Motor Vehicle Accident
Primary: Change in Frequency of Cellphone Unlocks — 0.26; 0.52; -0.95; 1.08 Phone unlocks per hour — p=0.12
Myopia-Night Blindness
Primary: Night Myopia — -0.30; -0.32 D
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1C at Week 20 — -1.10; -0.69 A1C (%) — p=<0.001
Hypertension
Primary: Adverse Events (AEs) — 9; 16; 8; 9 Participants
Caregiver · Disabled Veterans · Referred to Long-term Care
Primary: Patient Days in the Community (e.g. Days Not in Emergency Department, Inpatient, or Nursing Home Setting) — 352.87; 353.62 days
Leukemia, Myeloid, Acute
Primary: Part B: Percentage of Participants Who Achieved Complete Response (Complete Response Rate) Based on Investigator Assessment — 11.9; 16.6 Percentage of participants…
Adult Not Younger Than 65 Years
Primary: Number of Participants With Adverse Reactions — 80; 1 Participants
Fecal Incontinence
Primary: Responder Rate in Number of Fecal Incontinence Episodes — 64.4 percentage of responders
Healthy Subjects
Primary: Maximum Observed Plasma Concentration (Cmax) of Guaifenesin — 876 ng/mL
Influenza
Primary: Number of Participants With Maximum Systemic Reaction After Vaccination 1 — 16; 15; 9; 6 Participants
Phenylketonuria
Primary: Blood Phenylalanine Concentration — 1168.8; 617.6 umol/L
Type1 Diabetes Mellitus
Primary: System Suitability — 5; 4.8; 5 score on a scale